Clinical Trial Update: Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating omalizumab for individuals with chronic obstructive pulmonary disease and allergen sensitization is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Diseases
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Omalizumab (Omalizumab)

Snippet

Sponsor: Johns Hopkins University | Conditions: Chronic Obstructive Pulmonary Disease (COPD), Allergies | Phase 2 | Status: RECRUITING